



BRIVARACETAM tablets and oral solution (Briviact®▼) for the treatment of epilepsy in children and adolescents

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of BRIVARACETAM tablets or oral solution (Briviact®▼) for the treatment of epilepsy in children and adolescents.

Brivaracetam has been granted a license extension and is now indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. It was previously only licensed for use in epileptic patients from 16 years of age.

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, suitable treatment will be initiated by a specialist with training and expertise in epilepsy in adolescents and children, in accordance with the existing [Pan Mersey guidance](#), and formulary recommendations.

Please refer to the existing Pan Mersey policy statement for the use of [brivaracetam in adults](#) (from 16 years of age).

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.